Lipeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lipeng Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hong Yang
Department of Medical Ultrasound, the First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 shared publications - Jinshu Pang
Department of Medical Ultrasound, the First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 shared publications - Xiu-Mei Bai
Department of Medical Ultrasound, the First Affiliated Hospital of Guangxi Medical University, Nanning, China
3 shared publications - Yun He
Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
3 shared publications - Jiamin Chen
Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
2 shared publications - Li Liang
Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China
2 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47262
Ferroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study
Hepatocellular carcinoma (HCC), characterized by elevated incidence and mortality rates, has a considerable economic impact worldwide. The function of ferroptosis within the tumor microenvironment of HCC is crucial, and the specific contributions of ferroptosis-related genes (FRGs) are yet to be fully explored. FRG expression levels and relevant clinical data were sourced from The Cancer Genome Atlas. Two distinct ferroptosis-related subtypes were identified in liver cancer and their interrelationships were comprehensively examined. Using Cox regression and least absolute shrinkage and selection operator regression analysis, we created a predictive model based on FRGs to forecast overall survival and assess the potential benefits of immunotherapy in patients with HCC. Quantitative reverse transcription-polymerase chain reaction and IHC assays were conducted on clinical HCC specimens to validate the key FRGs. Significant differences in gene mutations, immune reactions, and prognostic outcomes were observed between the 2 distinct ferroptosis-related subtypes. An eight-gene signature consisting of SLC1A5, KIF20A, SLC7A11, CARS1, MYCN, PRDX6, GPX4, and KLF2 was established as a predictive model for liver cancer and was validated against data from GSE76427 and the International Cancer Genome Consortium cohorts. According to the FRG model, individuals classified as low-risk exhibited more favorable survival prospects compared to their high-risk counterparts ( P < .05). Overall, our investigation highlights the promise of FRGs as prognostic biomarkers and immunotherapy response in HCC, providing a novel approach for personalized patient management.
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47262
Open AccessFerroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study
Hepatocellular carcinoma (HCC), characterized by elevated incidence and mortality rates, has a considerable economic impact worldwide. The function of ferroptosis within the tumor microenvironment of HCC is crucial, and the specific contributions of ferroptosis-related genes (FRGs) are yet to be fully explored. FRG expression levels and relevant clinical data were sourced from The Cancer Genome Atlas. Two distinct ferroptosis-related subtypes were identified in liver cancer and their interrelationships were comprehensively examined. Using Cox regression and least absolute shrinkage and selection operator regression analysis, we created a predictive model based on FRGs to forecast overall survival and assess the potential benefits of immunotherapy in patients with HCC. Quantitative reverse transcription-polymerase chain reaction and IHC assays were conducted on clinical HCC specimens to validate the key FRGs. Significant differences in gene mutations, immune reactions, and prognostic outcomes were observed between the 2 distinct ferroptosis-related subtypes. An eight-gene signature consisting of SLC1A5, KIF20A, SLC7A11, CARS1, MYCN, PRDX6, GPX4, and KLF2 was established as a predictive model for liver cancer and was validated against data from GSE76427 and the International Cancer Genome Consortium cohorts. According to the FRG model, individuals classified as low-risk exhibited more favorable survival prospects compared to their high-risk counterparts ( P < .05). Overall, our investigation highlights the promise of FRGs as prognostic biomarkers and immunotherapy response in HCC, providing a novel approach for personalized patient management.
- 5 February 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (8) , 3516-3529
Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma
Purpose We aimed to develop and validate a combined model integrating radiomic features derived from Contrast-Enhanced Ultrasound (CEUS) images and clinical parameters for preoperative prediction of CK19-positive status in hepatocellular carcinoma (HCC). Methods A total of 434 patients who underwent CEUS and surgical resection from January 2020 to December 2023 were included. Patients were randomly divided into a training cohort (n = 304) and a validation cohort (n = 130). Radiomic features were extracted from multiphase CEUS images, including two-dimensional ultrasound (US), arterial, portal venous, and delayed phases, and combined to derive a Radscore model. Subsequently, a Combined Model was constructed using the Radscore and clinical parameters. Model performance was assessed using calibration, discrimination, and clinical utility. Results Multivariate logistic regression analysis identified Radscore (OR = 10.054, 95% CI: 5.931–19.120, p < 0.001) and AFP levels > 200 ng/mL (OR = 5.027, 95% CI: 2.089–12.784, p < 0.001) as significant predictors in the combined model. The AUC (Area Under the Curve) for the Combined Model was 0.954 in the training cohort and 0.927 in the validation cohort, compared to 0.939 and 0.917 for the Radscore Model alone. Calibration curves demonstrated strong concordance between predicted and actual outcomes. Decision curve analysis (DCA) showed that both the Radscore Model and the Combined Model exhibited good net benefits across a wide range of threshold values in both the training and validation cohorts. Conclusion The Radscore based on CEUS, combined with the serum markers AFP > 200 ng/L to construct a Combined Model, shows good predictive performance for CK19 + hepatocellular carcinoma (HCC).
- 5 February 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (8) , 3516-3529
Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma
Purpose We aimed to develop and validate a combined model integrating radiomic features derived from Contrast-Enhanced Ultrasound (CEUS) images and clinical parameters for preoperative prediction of CK19-positive status in hepatocellular carcinoma (HCC). Methods A total of 434 patients who underwent CEUS and surgical resection from January 2020 to December 2023 were included. Patients were randomly divided into a training cohort (n = 304) and a validation cohort (n = 130). Radiomic features were extracted from multiphase CEUS images, including two-dimensional ultrasound (US), arterial, portal venous, and delayed phases, and combined to derive a Radscore model. Subsequently, a Combined Model was constructed using the Radscore and clinical parameters. Model performance was assessed using calibration, discrimination, and clinical utility. Results Multivariate logistic regression analysis identified Radscore (OR = 10.054, 95% CI: 5.931–19.120, p < 0.001) and AFP levels > 200 ng/mL (OR = 5.027, 95% CI: 2.089–12.784, p < 0.001) as significant predictors in the combined model. The AUC (Area Under the Curve) for the Combined Model was 0.954 in the training cohort and 0.927 in the validation cohort, compared to 0.939 and 0.917 for the Radscore Model alone. Calibration curves demonstrated strong concordance between predicted and actual outcomes. Decision curve analysis (DCA) showed that both the Radscore Model and the Combined Model exhibited good net benefits across a wide range of threshold values in both the training and validation cohorts. Conclusion The Radscore based on CEUS, combined with the serum markers AFP > 200 ng/L to construct a Combined Model, shows good predictive performance for CK19 + hepatocellular carcinoma (HCC).
- 23 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (5) , 2046-2059
Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma
TAT, a widely used treatment for HCC, can exacerbate the progression of residual HCC. The present study investigated the mechanism of action of PLK1 following ITA of HCC. The PLK1 levels in HCC were determined using qRT-PCR from clinical patient samples, IHC from tissue microarray, and data from globally high-throughput data and microarrays. The PLK1 levels and their effect on the biological phenotype of heat-stress HCC cells were evaluated through in vitro experiments. We detected PLK1 abnormal expression in HCC models of nude mice subjected to ITA. We detected the effects of different PLK1 expression levels on EMT pathway proteins. PLK1 exhibited an overexpression in HCC tissues with an SMD of 1.19 (3414 HCC and 3036 non-HCC tissues were included), distinguishing HCC from non-HCC effectively (AUC = 0.9). The qRT-PCR data from clinical HCC patient samples and IHC from HCC tissue microarray results also indicated an overexpressed level. In the incomplete ablation models, an increased PLK1 expression was found in both heat-stress cells and subcutaneous tumors. The upregulation of PLK1 following ITA was found to enhance the malignancy of HCC and exacerbate the proliferation, migration, and invasion of residual HCC cells, whereas PLK1 knockdown suppressed the biological malignancy of HCC cells. Meanwhile, PLK1 has different regulatory effects on various EMT pathway proteins. PLK1 promotes the progression of residual HCC by activating EMT pathway after ITA, which might provide a novel idea for the treatment and prognosis of residual HCC.
- 23 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (5) , 2046-2059
Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma
TAT, a widely used treatment for HCC, can exacerbate the progression of residual HCC. The present study investigated the mechanism of action of PLK1 following ITA of HCC. The PLK1 levels in HCC were determined using qRT-PCR from clinical patient samples, IHC from tissue microarray, and data from globally high-throughput data and microarrays. The PLK1 levels and their effect on the biological phenotype of heat-stress HCC cells were evaluated through in vitro experiments. We detected PLK1 abnormal expression in HCC models of nude mice subjected to ITA. We detected the effects of different PLK1 expression levels on EMT pathway proteins. PLK1 exhibited an overexpression in HCC tissues with an SMD of 1.19 (3414 HCC and 3036 non-HCC tissues were included), distinguishing HCC from non-HCC effectively (AUC = 0.9). The qRT-PCR data from clinical HCC patient samples and IHC from HCC tissue microarray results also indicated an overexpressed level. In the incomplete ablation models, an increased PLK1 expression was found in both heat-stress cells and subcutaneous tumors. The upregulation of PLK1 following ITA was found to enhance the malignancy of HCC and exacerbate the proliferation, migration, and invasion of residual HCC cells, whereas PLK1 knockdown suppressed the biological malignancy of HCC cells. Meanwhile, PLK1 has different regulatory effects on various EMT pathway proteins. PLK1 promotes the progression of residual HCC by activating EMT pathway after ITA, which might provide a novel idea for the treatment and prognosis of residual HCC.